JP Morgan Maintains Neutral on Ionis Pharmaceuticals, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains a Neutral rating on Ionis Pharmaceuticals but raises the price target from $50 to $55.
August 26, 2024 | 2:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan has maintained a Neutral rating on Ionis Pharmaceuticals but increased the price target from $50 to $55, indicating a slightly more positive outlook.
The increase in the price target from $50 to $55 suggests a more optimistic view on Ionis Pharmaceuticals' future performance, which could positively influence investor sentiment and potentially lead to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100